Creatine: From Gym Supplement to Cancer-Fighting Ally
Creatine, the organic acid widely used by athletes and bodybuilders to build muscle, may have an entirely different superpower: energizing the immune system's most critical cancer-fighting cells. A new study from UCLA, published in iScience, reveals that creatine fuels dendritic cells — the specialized immune cells that detect tumors and direct killer T cells to attack them.
Most approved cancer immunotherapies work by targeting killer T cells directly, yet only about 20 to 40 percent of patients respond. The UCLA team believes that improving the function of dendritic cells, which coordinate and direct those T cells, could make immunotherapy effective for far more people. This discovery follows closely on recent breakthroughs in metabolic protein research that have opened new frontiers in understanding how the body's cellular machinery regulates health and disease.
How Creatine Powers Dendritic Cells Inside Tumors
The researchers, led by senior author Prof. Lili Yang of the UCLA Broad Stem Cell Research Center, discovered that dendritic cells ramp up their intake of creatine inside the tumor microenvironment — a nutrient-poor, hostile environment where immune cells must compete with rapidly growing cancer cells for energy.
Using metabolomics analyses, the team found that creatine supplementation raised intracellular ATP levels in dendritic cells. ATP is the energy currency cells use to power virtually every function. This energy boost sustained the key inflammatory signaling pathways needed for dendritic cells to activate T cells effectively, similar to how targeted metabolic compounds have been shown to restore cellular function in neurodegenerative diseases.
Mouse Models Show Dramatic Tumor Growth Reduction
In mouse models of melanoma, daily creatine injections significantly slowed tumor growth and boosted both the abundance and activation of tumor-infiltrating dendritic cells. Creatine-treated dendritic cells also produced higher levels of chemical signals that draw additional immune cells into the tumor, amplifying the anti-cancer response.
To confirm creatine's essential role, the team engineered dendritic cells that lacked the creatine transporter entirely. These cells showed impaired survival, reduced activation, and a weakened ability to prime T cells. When grown alongside T cells in laboratory experiments, the T cells multiplied less and produced fewer signaling molecules needed for an effective anti-cancer response.
Human Cell Experiments Confirm the Mechanism
The results extended to human cells. Creatine treatment enhanced the activation of human monocyte-derived dendritic cells, which are commonly used to develop dendritic cell cancer vaccines. The treated cells improved their ability to stimulate human T cells against a cancer-associated target.
"The potential we see here is that creatine could be used in two complementary ways: as a supplement to enhance the immune response of patients already receiving immunotherapy, and as a tool to improve the quality of dendritic cell-based vaccines before administration," said James Elsten-Brown, a co-first author of the study.
Building on Earlier Discoveries
This study builds directly on earlier work from the same UCLA lab showing that creatine powers killer T cells directly. The new findings reveal that creatine's immune-boosting effects are even broader than previously understood, energizing not just the "soldiers" but also the "generals" that direct them.
"Understanding how to metabolically support dendritic cells is about supporting the entire anti-tumor response, not just the killer T cells at the end of it," said Elliot Kang, a co-first author and former undergraduate researcher in Yang's lab.
What This Means for Cancer Patients
Current immunotherapies like checkpoint inhibitors (such as Keytruda and Opdivo) work by releasing brakes on T cells, but many patients' tumors lack the pre-existing T cell activity needed for these drugs to work. By improving dendritic cell function, creatine supplementation could help convert "cold" tumors — those without immune activity — into "hot" tumors that respond to immunotherapy.
Importantly, creatine is already an FDA-approved, over-the-counter supplement with a well-established safety profile. This could significantly accelerate the path to clinical testing, as researchers would not need to start from scratch with safety studies.
India Impact: A Low-Cost Boost for Immunotherapy Access
For India, where cancer incidence is projected to rise from 1.46 million new cases in 2022 to over 2 million by 2040, an affordable intervention that enhances immunotherapy could be transformative. Creatine supplements are readily available in India at low cost (roughly ₹500–₹1,500 per month). If clinical trials confirm the effect in humans, it could offer a practical way to improve outcomes without expensive new biologics or infrastructure.
Study Limitations and Next Steps
The findings are currently preclinical and have not yet been validated in human patients. The UCLA team is planning further studies to determine optimal dosing, timing, and whether creatine works across different cancer types. Researchers caution that patients should not begin high-dose creatine supplementation without consulting their oncologists, as interactions with existing treatments are not yet understood.
FAQ
What were the key findings of this study?
Creatine boosts the activity and survival of dendritic cells, enabling them to better activate cancer-killing T cells. In mouse models, creatine supplementation slowed melanoma tumor growth. Human dendritic cells in the lab also responded to creatine treatment.
Is creatine already approved for human use?
Yes, creatine is an FDA-approved dietary supplement widely used for athletic performance. It has a well-established safety profile at standard doses, though cancer-specific studies are still needed.
Can I start taking creatine to fight cancer?
No. These are preclinical findings in mice and lab-grown human cells. Patients should consult their oncologist before making any changes to their supplement regimen. Clinical trials are needed to confirm the effect in humans.
How does this compare to existing immunotherapies?
Existing immunotherapies like checkpoint inhibitors target T cells directly. Creatine appears to support the upstream cells (dendritic cells) that activate those T cells, potentially making existing therapies effective for a wider range of patients.
Sources
Sources:
